JP7557465B2 - Ｉｌ－１５組成物およびその使用方法 - Google Patents

Ｉｌ－１５組成物およびその使用方法 Download PDF

Info

Publication number
JP7557465B2
JP7557465B2 JP2021534270A JP2021534270A JP7557465B2 JP 7557465 B2 JP7557465 B2 JP 7557465B2 JP 2021534270 A JP2021534270 A JP 2021534270A JP 2021534270 A JP2021534270 A JP 2021534270A JP 7557465 B2 JP7557465 B2 JP 7557465B2
Authority
JP
Japan
Prior art keywords
seq
homodimer
activatable proprotein
cleavage
ggs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021534270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513888A (ja
JPWO2020123980A5 (https=
JP2022513888A5 (https=
Inventor
ジージュアン リー，
Original Assignee
プロヴィヴァ セラピューティクス （ホン コン） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロヴィヴァ セラピューティクス （ホン コン） リミテッド filed Critical プロヴィヴァ セラピューティクス （ホン コン） リミテッド
Publication of JP2022513888A publication Critical patent/JP2022513888A/ja
Publication of JPWO2020123980A5 publication Critical patent/JPWO2020123980A5/ja
Publication of JP2022513888A5 publication Critical patent/JP2022513888A5/ja
Priority to JP2024159011A priority Critical patent/JP2024175026A/ja
Application granted granted Critical
Publication of JP7557465B2 publication Critical patent/JP7557465B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021534270A 2018-12-14 2019-12-13 Ｉｌ－１５組成物およびその使用方法 Active JP7557465B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024159011A JP2024175026A (ja) 2018-12-14 2024-09-13 Ｉｌ－１５組成物およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779793P 2018-12-14 2018-12-14
US62/779,793 2018-12-14
PCT/US2019/066287 WO2020123980A1 (en) 2018-12-14 2019-12-13 Il-15 compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024159011A Division JP2024175026A (ja) 2018-12-14 2024-09-13 Ｉｌ－１５組成物およびその使用方法

Publications (4)

Publication Number Publication Date
JP2022513888A JP2022513888A (ja) 2022-02-09
JPWO2020123980A5 JPWO2020123980A5 (https=) 2022-12-06
JP2022513888A5 JP2022513888A5 (https=) 2022-12-06
JP7557465B2 true JP7557465B2 (ja) 2024-09-27

Family

ID=71075819

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021534270A Active JP7557465B2 (ja) 2018-12-14 2019-12-13 Ｉｌ－１５組成物およびその使用方法
JP2024159011A Pending JP2024175026A (ja) 2018-12-14 2024-09-13 Ｉｌ－１５組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024159011A Pending JP2024175026A (ja) 2018-12-14 2024-09-13 Ｉｌ－１５組成物およびその使用方法

Country Status (8)

Country Link
US (1) US20230045048A1 (https=)
EP (1) EP3893917A4 (https=)
JP (2) JP7557465B2 (https=)
KR (1) KR102911817B1 (https=)
CN (1) CN114746105A (https=)
AU (1) AU2019395266A1 (https=)
CA (1) CA3121813A1 (https=)
WO (1) WO2020123980A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
MX2022007202A (es) * 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2021257808A2 (en) * 2020-06-17 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
JP2024511387A (ja) 2021-03-16 2024-03-13 シートムエックス セラピューティクス，インコーポレイテッド マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
US20240228585A1 (en) * 2021-05-03 2024-07-11 President And Fellows Of Harvard College Fc-fusion protein therapeutic for the treatment of pancreatitis
EP4580683A2 (en) * 2022-08-31 2025-07-09 Proviva Therapeutics (Hong Kong) Limited Il-15 procytokine antibody fusion proteins
AU2023338694A1 (en) * 2022-09-08 2025-04-03 Cugene Inc. Novel pd1-targeted il-15 immunocytokine and vitokine fusions
WO2024216170A2 (en) * 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2025085744A1 (en) * 2023-10-18 2025-04-24 Memorial Sloan-Kettering Cancer Center Fusion polypeptides and uses thereof
WO2025180355A1 (zh) * 2024-02-27 2025-09-04 江苏奥赛康生物医药有限公司 Il-15前药与免疫检查点抑制剂的组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
JP2015509952A (ja) 2012-02-28 2015-04-02 ザ ユニバーシティ オブ バーミンガム 免疫療法分子および使用
JP2018518972A (ja) 2015-06-26 2018-07-19 ユニバーシティ オブ サザン カリフォルニア 腫瘍特異的活性化のためのマスキングキメラ抗原受容体ｔ細胞

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US20110178279A1 (en) * 2009-08-03 2011-07-21 Williams John C Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
JP5861223B2 (ja) * 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
WO2016004383A1 (en) * 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
WO2017201352A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
CN110214147A (zh) * 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
KR20190102259A (ko) * 2017-01-10 2019-09-03 인트렉손 코포레이션 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
JP2015509952A (ja) 2012-02-28 2015-04-02 ザ ユニバーシティ オブ バーミンガム 免疫療法分子および使用
JP2018518972A (ja) 2015-06-26 2018-07-19 ユニバーシティ オブ サザン カリフォルニア 腫瘍特異的活性化のためのマスキングキメラ抗原受容体ｔ細胞

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mol. Cancer Ther，Vol.8, No.9，2009年，pp.2736-2745
Scientific Reports，2018年，Vol.8, No.7675， pp.1-11

Also Published As

Publication number Publication date
WO2020123980A1 (en) 2020-06-18
EP3893917A1 (en) 2021-10-20
US20230045048A1 (en) 2023-02-09
EP3893917A4 (en) 2023-01-11
CA3121813A1 (en) 2020-06-18
JP2022513888A (ja) 2022-02-09
CN114746105A (zh) 2022-07-12
KR20210104060A (ko) 2021-08-24
AU2019395266A1 (en) 2021-06-17
KR102911817B1 (ko) 2026-01-14
JP2024175026A (ja) 2024-12-17

Similar Documents

Publication Publication Date Title
JP7557465B2 (ja) Ｉｌ－１５組成物およびその使用方法
JP7631420B2 (ja) ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法
US20240254184A1 (en) Il-15 fusion proteins and methods of making and using the same
HK40106026A (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
HK40098241A (zh) Il-15融合蛋白以及制备和使用其的方法
EA052095B1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
HK40044003A (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
HK40044003B (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240913

R150 Certificate of patent or registration of utility model

Ref document number: 7557465

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150